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Abstract 
Past research suggested that lutein (L) and zeaxanthin (Z) play a role in many 
aspects of cognitive functions including motor speed, working memory, executive 
function, psychomotor speed and verbal fluency among elderly people.  Moreover, L and 
Z are the only carotenoids found in the eye, and they are correlated with improved 
contrast sensitivity, improved temporal vision, reduced glare disability, and reduced risk 
of age related-macular degeneration (AMD).  Animal and postmortem research suggests 
that MPOD may be a biomarker for predicting cognitive decline with age.  The purpose 
of this study is to evaluate the potential relationship between MPOD and cognition in 
young healthy adults.  There were fifty participants in the current study, 25 had low 
MPOD. The remaining participants exhibited high MPOD, which was measured using a 
macular pigment densitometer.  People with low MPOD did not perform any worse than 
people with high MPOD.  Although low MPOD in young adults may be a biomarker for 
future cognitive decline, the effects may lay dormant until later in life.  Future research 
should explore this possibility by replicating this study with an older population.   
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There are about 600 carotenoids that occur in nature and of these, approximately 
40 are found in the human diet (Ma & Ming Lin, 2010; Zimmer & Hammond, 2007). 
 About 20 can be detected in blood serum and only two, lutein (L) and zeaxanthin (Z), 
cross the blood-retinal barrier and can be found in the eye (Hammond, 2008; Ma & Ming 
Lin, 2010).  Carotenoids are not manufactured within the human body, and must be 
acquired through a diet high in green leafy vegetables and other yellow, orange or red 
pigmented vegetables (Zimmer & Hammond, 2007). Dark fruits (e.g., blueberries) are 
also high in carotenoids. The two subclasses of carotenoids are carotenes and 
xanthophylls. Both types include one hydrogen atom and one carbon atom, with the key 
difference being that xanthophylls are oxygenated (Krinsky, Landrum & Bone, 2003).  
Carotenoids are believed to serve an antioxidant function within the body, and help 
protect against damage caused by free radicals that result from harmful environmental 
agents, including smoking, stress, pollution, and UV radiation.    
The health benefits of these micronutrients are far reaching.  For instance, beta-
carotene can be metabolized into vitamin A, which is involved in the repair of body tissue 
and the maintenance of a strong immune system.  Unlike vitamin A, beta-carotene is not 
toxic when taken in high doses, and can be stored by the body until it is needed, which 
makes it safer than a diet high in vitamin A.  Other research suggest that beta-
cryptoxanthin, lycopene, lutein and zeaxanthin may play a role in reducing the risk of 
lung cancer, and lycopene is correlated with reduced risk of prostate cancer (Stringham, 
Bovier, Wong & Hammond, 2010).  
 Of the 16 carotenoids found within the brain, the xanthophylls lutein (L) and 
zeaxanthin (Z) make up 66% to 77% of the total amount of carotenoids found within the 
2 
 
brain and they are distributed among four regions including the cerebellum, the frontal 
lobe, the pons and the occipital cortex (Johnson, 2012; Polidori, De Spirt, Stahl & 
Pientka, 2012; Renzi & Hammond, 2009; Vishwanathan, Neuringer, Snodderly, Schalch 
& Johnson, 2013; Zimmer & Hammond, 2007).  Research has suggested that they play a 
role in many aspects of cognitive functions including motor speed, working memory, 
executive function, psychomotor speed and verbal fluency among the elderly.  They may 
also slow the progression of age-related cognitive disorders such as Alzheimer’s disease 
(Johnson, 2012).    Moreover, L and Z are the only two carotenoids found in the eye, and 
they are correlated with improved contrast sensitivity, improved temporal vision, reduced 
glare disability, and reduced risk of age related-macular degeneration (AMD) (Ciulla & 
Hammond, 2004; Ma &Ming Le, 2010; Renzi & Hammond, 2010).  They may also 
contribute to slowing the progression of AMD.  
It is interesting that L and Z appear to play such a salient role by protecting both 
the brain and the eye from age-related degenerative disorders.  This exploratory study 
evaluated the potential relationship between L and Z in the eye as they correlate with L 
and Z in the brain among young healthy participants, to see whether differences exist on 
cognitive task performance in young, college-age participants with low vs. high macular 
pigment as there appears to be in older individuals. That is, do the benefits of high 
macular pigment show themselves in early adulthood?  Also, are there any 
negative/detrimental effects of low macular pigment in this age group?   
Prior to addressing these questions in the current study, a detailed discussion of  
the role of L and Z  in vision and cognitive function is provided as a background for 
understanding the interaction of carotenoid levels in the retina and cognitive functions. 
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Ocular Heath and L an Z:  
It is well known that L and Z are found in their highest concentrations within the 
foveal region of the retina and form the macula lutea, also known as the macular pigment. 
Research shows that macular pigment protects the eye by acting as an antioxidant, and by 
filtering harmful short wavelength light from reaching the retina and causing damage.  
Specifically, macular pigment plays an integral role by making the eye less sensitive to 
the effects of blue light, forming a natural blue light blocking sunglasses effect 
(Hammond & Fletcher, 2012).  The macula can absorb up to 90% of the blue light going 
through the retina at 460 nm, which is the peak wavelength in the macular pigment 
optical density spectrum (MPOD).  In order to evaluate macular pigment levels, an 
instrument known as a Macular Pigment Densitometer is used; this utilizes 
heterochromatic flicker photometry (HFP).  HFP is used to compare two similar light 
sources. The lights are presented in counter phase which produces a flickering sensation. 
The densitometer presents a critical flicker fusion task at a one degree angle from the 
center of the fovea. The task involves presenting a blue light 460 nm in counter phase, 
with a green light 570 nm (Ciulla & Hammond, 2004; Hagen, Krebs, Glittenberg & 
Binder, 2010; Hammond & Wooten, 2005; Krinsky, Landrum & Bone, 2003; Snodderly, 
Mares, Wooten, Oxton, Gruber & Ficek, 2004; Wooten & Hammond, 2005; Wooten, 
Hammond, Land & Snodderly, 1999).   The green light is used as a reference because it is 
outside the range of wavelengths that macular pigment absorbs.  The participant slowly 
adjusts the rate of modulation in the blue light by turning a button on the densitometer 
until the flicker is no longer visible.  This occurs when the luminosities of the opposing 
light sources are matched at the level of the photoreceptors.  At this point the 
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experimenter instructs the participant to continue to adjust the rate of modulation until the 
subject sees the flickering light again.  Once this is done, the participant is instructed to 
find the center of the no flicker zone.  This data can then be used to get an accurate 
estimate of macular pigment ocular density (MPOD) because it is assumed that people 
with higher MPOD will require higher blue light intensity in order to compensate for the 
attenuation of blue light by macular pigment (Krinsky, Landrum & Bone, 2003).  
However, the lens also plays a role in the amount of blue light needed to minimize 
flicker.   Therefore, it is necessary to repeat this process at a seven degree angle from the 
center of the fovea.  The parafoveal measurement provides insight into what role the lens 
plays in blue light absorption.   
The protective benefits of macular pigment have been illustrated in multiple 
research studies evaluating the relationship between macular pigment and real world 
visual processing.  For instance, earlier research regarding visual health began by looking 
at factors that predicted differences in people’s ability to see varying contrast known as 
contrast sensitivity (CS) and also focused on their ability to adjust to glare conditions or 
glare disability (GD).  In order to take (CS) measurements, an instrument known as a 
Vector Vision CVS 1000 was used.  This apparatus measures contrast at 2, 4, 6 and 8 
c/deg.  Glare disability (amount of visual interference experienced by a participant under 
glare conditions) was measured by turning on two lights attached to the 4 c/deg cycle row 
on the CVS 1000 that mimic an approaching vehicle’s head lights at 20 feet.  A 
participant’s glare disability score was calculated by subtracting the participant’s glare 
score from his/her score at the 4 c/deg row under a no-glare condition. The Vector Vision 
test consists of four rows of backlit circular contrast gradients.  Each row had a series of 7 
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light pairs (columns) with one light appearing directly above the other. One of the lights 
contained a set of vertical lines that matched the lines on a template appearing on the left 
side of the rows. The other lights did not contain a gradient. Participants were asked to 
specify verbally whether the gradient lines were on the “top”, “bottom” or “neither” 
column within a specific row for each of 7 light pairs within a row.  People with higher 
MPOD did better than those with lower MPOD on both the contrast and glare disability 
tasks (Holloway, Nanez, Hammond, Jorgenson & Zimmerman, 2001).   
Additional research involving glare disability was conducted in order to find out 
whether L and Z supplementation improves participants’ ability to adjust to glare.  This 
experiment used similar equipment to the previous study.  However, in this study 
participants were instructed to increase the intensity of the glare source until they could 
no longer see the gradient lines.  Participants were supplemented with 10 mg of L and 2 
mg of Z for 6 months (Stringman, Bovier, Wong & Hammond, 2010).  The participants 
all exhibited improved MPOD after supplementation and on average were able to 
withstand 58% greater intensity of glare before no longer being able to see the gradient.   
This research led to additional studies evaluating the relationship between contrast 
sensitivity and glare disability among participants diagnosed with macular degeneration.  
Over time, oxidative damage to the macula leads to age-related macular degeneration 
(AMD).  The risk of AMD is increased for people with low MPOD (Ciulla & Hammond, 
2004).  Early stages of AMD tend to be asymptomatic, but as the disease progresses, it 
eventually leads to central vision blindness.  AMD is the leading cause of blindness in 
western culture, and AMD prevalence rates increase with age.  For instance, about 2% of 
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American’s between the age of 40 and 49 have intermediate AMD and .1% have 
advanced AMD (Renzi & Johnson, 2007).  Moreover, the numbers increase dramatically 
and prevalence rates among people between 70 and 79 are 12% and 2.4%, respectively, 
while prevalence increases to 23.6% and 11.8% for people over 80. Currently, there is no 
cure for AMD and research has been focused on strategies that show promise for slowing 
down the progression of the disease. 
The Lutien Antioxidant Supplementation Trial was a double blind placebo 
controlled study that contributed the most to the current paradigm for slowing the 
progression of AMD (Richer, Stiles, Statkute, Pulido, Frankowski, Rudy, Pei, Tsipursky 
& Nyland, 2004; Renzi & Johnson, 2007).  In this 12 month longitudinal study, 90 
participants were randomly assigned to one of three groups.  Two experimental groups 
were compared to a control group that received only a maltodextrin placebo (i.e, suger 
pill).  The first experimental group received 10 mg of lutein while the other experimental 
group received 10 mg of lutein with additional carotenoids and multivitamins.   The goal 
of this study was to evaluate the relationship between supplementation and MPOD, 
contrast sensitivity, and glare disability among participants diagnosed with AMD.  After 
a year of supplementation, the research found that participants supplemented with lutein 
only had a mean MPOD improvement of 36% and participants supplemented with lutein 
and antioxidants had a mean MPOD improvement of 43%.  MPOD declined slightly in 
the placebo group.    Both of the experimental groups also exhibited improved acuity, 
increased contrast sensitivity and reduced glare disability with the lutein and antioxidant 
group performing slightly better than the lutein only group.  The results suggest that the 
progression of AMD can be slowed with an aggressive lutein and multivitamin regimen. 
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Cognition and L and Z: 
 Interestingly, research has shown that L and Z are also correlated with cognitive 
function among elderly populations, and animal research has been conducted to 
determine whether MPOD might be a reliable biomarker for xanthophyll concentrations 
within the brain (Johnson, 2012; Vishwanathan et al, 2013).    Specifically, a group of 
monkeys were put on a lifetime diet of monkey chow supplemented with L and Z.  After 
the monkeys were sacrificed, researchers used high-performance liquid chromatography 
to separate L and Z from retinal tissue and brain tissue.  Results showed that L and Z 
levels in the cerebellum were related to L and Z in the retina.  There was a trending 
correlation between L and Z levels in the occipital cortex when compared to L and Z in 
the retina.  Z concentrations in the retina were significantly related to Z levels found in 
the pons and in the frontal cortex.  
Human research suggests that L and Z serum levels are depleted for people with 
Alzheimer’s disease and Mild Cognitive Impairment (MCI).  Specifically, it has been 
reported that participants in the lowest quintile regarding cognitive measures had an 
increased likelihood of having low levels of total plasma carotenoids.  Low Z levels were 
correlated with decreased performance on cognitive tests evaluating scanning, processing 
speed, mental flexibility and executive function (Akbaraly, Faure, Gourlet, Favier & 
Berr, 2007).     
Moreover, a 4-month double masked supplementation study with L and DHA 
illustrated improved performance on a battery of cognitive tests (Johnson, 2012; Johnson, 
McDonald, Caldarella, Chung, Troen & Snodderly, 2008).  This research consisted of 49 
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women who were randomly assigned into one of three groups, a control (placebo only) 
group consisting of 10 women, and three experimental groups.   Fourteen women 
received only 800 mg of DHA while 11 women received only 12 MG of lutien.  The 
remaining women received a combination of DHA and lutien.  Supplementation 
improved verbal fluency scores for all experimental groups while the combination group 
displayed improved scores for memory as well.   This suggests that supplementation may 
help slow cognitive decline among elderly people at risk of developing MCI or 
Alzheimer’s disease. These findings are encouraging; however, the study needs to be 
replicated with a much larger participant population, in order to verify whether the 
findings are supported. 
In any case, some previous research points toward a positive relationship between 
L and Z and both visual abilities and cognitive processes.  Moreover, supplementation 
may reduce adverse effects on vision for people of all ages.  Supplementation may also 
slow the progression of cognitive impairment among the elderly.  Since HFP may serve 
as a noninvasive measurement of L and Z in brain tissue, the proposed exploratory study 
would be the first to use it among young healthy participants. The goal here is to evaluate 
the relationship between MPOD and cognition among young adults. As stated above, if 
there are differences in cognitive function among young adults with high vs. low MPOD 
it would indicate that such a relationship is present relatively early in development. If no 
significant differences are observed among this age group, but a trend is present, it would 
suggest low MPOD may be an early warning sign regarding development of future 
cognitive impairment with age. 
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Methods 
Participants 
Seventy-five participants from a large southwestern university were screened with 
a macular pigment densitometer in order to identify participants with high and low 
MPOD. Participants with average MPOD were excluded from the study. The 
experimenter explained to them that the study involved participants at the higher and 
lower ends of the MPOD spectrum. Participants not included in the study due to their 
average MPOD levels were thanked for their time and dismissed.  Participants’ MPOD 
levels were determined in accordance with Renzi and Hammond’s (2010) work that 
suggests low MPOD ranges between .00-.20 while high MPOD ranges between .41-1.  
After excluding 25 participants with average MPOD, the subject pool included 25 people 
with low MPOD and 25 people with high MPOD   (Males =14, Females =36, aged 18-40 
years) (Table 1).  All participants self-reported good ocular health, and had at least a best 
corrected visual acuity of 20/40 Snellen.    
Materials and Procedure   
HFP was used to assess MPOD.  This measurement has been validated on normal 
subjects, and prior research has tested the reliability of this method (Ciulla & Hammond, 
2004; Wooten, Hammond, Land & Snodderly, 1999).  It has been determined that with 
proper instruction, participants recruited from the general population can undergo testing 
and researchers will obtain reliable results.  Test stimuli were presented in the center of a 
6-degree, 10.5 cd/m2 470-nm circular background.  The test stimuli were presented in 
counter phase that included a 460 nm testing field and a 570 nm reference field.  The 
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radiance of the LEDs was between 11-12 Hz in the foveal condition and 6-7 Hz in the 
parafoveal condition.  Participants were instructed to focus on the center of the blue 
flickering circle and were allowed a practice trial to find the center of the no flicker zone.  
Participants then repeated this process six times and each participant’s average was 
calculated to get the foveal value.  After the first six trials, a red led light was turned on 
that participants saw on the left side of their visual field.  Participants were instructed to 
focus their central vision on the red LED while watching the blue light with their 
peripheral vision.  Participants were then instructed to find the no flicker zone six more 
times in order to obtain their parafoveal measurement.  The two averages were then used 
to calculate MPOD.  Following MPOD testing, all participants that met the visual acuity 
selection criteria were administered a battery of cognitive assessments provided by CNS 
Vital Signs (Table 2).  This consisted of an on-line set of tests that took about one hour to 
complete.  These tests measured 12 cognitive domains including reasoning, memory, 
psychomotor speed, reaction time, complex attention, cognitive flexibility, processing 
speed, executive function, verbal memory, visual memory, working memory and 
sustained attention.  Participants were advised to ask for clarification if they did not 
understand any of the test instructions and were also allowed to take breaks between 
assessments.  When a participant completed the tests, the experimenter evaluated the 
results of the test battery, which provided insight into the validity of the outcome for each 
domain.  If a subject received invalid results for any of the tests, he/she was re-
administered the instructions and retested in the areas that were deemed invalid. 
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Results  
 In order to determine whether a relationship between macular pigment level and 
cognition exists in young healthy individuals the analyses focused on the difference in 
cognitive scores for people with low MPOD as compared to people with high MPOD.  A 
2 (MPOD) x12 (Cognitive Domian) multivariate analysis of variance (MANOVA) was 
preformed with MPOD (high vs low) as a between subject factor predicting the twelve 
measures of cognitive ability.  The reason the MANOVA was used is because we were 
interested in examining the relationship between MPOD and the cognitive measures, 
namely, reasoning, memory, psychomotor speed, reaction time, complex attention, 
processing speed, executive function, verbal memory, visual memory, working memory 
and sustained attention. Moreover, a correlation matrix was preformed to show that most 
of the dependent variables were strongly related to each other which justifies using a 
MANOVA.  Analyses of the various cognitive scores revealed no significant relationship 
between MPOD levels and cognition, F(12,36) = .253,p = .456 (Tables 3,4).   
Discussion 
This study was highly exploratory in nature, and there may be many reasons for 
the lack of significant results.  Previous research has suggested that L and Z play a role in 
the maintenance of visual health for people of all ages and may also protect against 
cognitive decline for the elderly.  However, the research suggesting that MPOD can be 
used as a biomarker in order to determine the amount of L and Z that people have in their 
brain tissue is in its infancy, limited to research with elderly participants to date.  
Although animal research and postmortem research on humans have suggested that 
MPOD is a reliable indicator of xanthophyll levels in brain tissue, only one other study 
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has attempted to compare MPOD to cognitive function (Johnson, 2012; Johnson et al, 
2006).  This study measured MPOD and serum levels of L in a group of women that 
underwent four weeks of supplementation and took a battery of cognitive tests both pre- 
and post-supplementation.  Participants supplemented with L and DHA had the most 
improved cognitive scores and had the largest increase of lutein in the macula.  This 
suggests that amount of lutein in an individual’s diet may not be as important as how it is 
transported across the blood brain barrier.  
Specifically, research of Johnson et al (2006) suggests that while lutein is 
important with regards to cognitive improvement among the elderly, a balanced long-
term diet that helps facilitate the absorption and transport of nutrients across the blood 
brain barrier may be essential in order to receive the best results from supplementation.  
Although this study found that MPOD did not correlate with cognition the increased level 
of L in the retina may also suggest increased concentrations in other brain areas.  It is 
noteworthy that this was a healthy group of women and MPOD tends to remain constant 
for people that maintain a healthy lifestyle.  It is possible that including all MPOD levels 
made it impossible to see any potential effects on cognition.  Therefore, it may be 
beneficial to replicate this study while excluding people with average MPOD because this 
may illustrate that individuals with low MPOD preform significantly worse on cognitive 
tests when compared to people with high MPOD.   
The above findings could help develop insight into the weaknesses of the current 
study and suggest future directions for this type of research.  It is clear that some of the 
participants in this study have low MPOD, yet their performance on the cognitive tests 
did not differ from that of  participants with high MPOD.  This could be related to the 
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degenerative nature of mild cognitive impairment.  Although these people may be at risk 
of future cognitive impairment, the effects may be dormant until later in life.  Therefore, 
it may be advantageous for future research to replicate the current study within an older 
population.  Also all the participants in the current study were university students. It is 
possible that being in an environment that encourages constant intellectual exercise may 
protect them from experiencing or exhibiting any early indications of cognitive decline.  
Therefore, replicating the study in the general population may produce different results 
with young people.   
An alternative way to find out whether MPOD can be used as a biomarker for 
cognition would be to conduct a longitudinal study.  This research could recruit 
participants without any signs of cognitive impairment and follow them across time.  
Participants with average MPOD should not be included in the study.  All qualifying 
participants should undergo MPOD testing and cognitive evaluation every five years.  
This would enable researchers to see at what age MPOD is indicative of impaired 
cognitive function if a relationship is found to exist, as previous research with older 
subjects suggests.  Moreover, this would also provide the opportunity to conduct further 
studies to continue exploring the role of L and Z supplementation on participants 
experiencing the earliest sign of cognitive impairment, as well as on participants with 
different levels of MPOD.  Future studies may also explore the relationship between 
MPOD and cognitive function and other factors, such as behavior (e.g. smoking, alcohol 
consumption, UV sunglass wear), long-term dietary differences, gender, and ethnicity, 
for example.  
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In sum, as stated above, the fact that the current study did not find differences in 
cognitive abilities between university students with low vs. high MPOD, may be due to 
the fact that the they are young and, although they differ in MPOD levels, harmful effects 
of low MPOD may not appear until later in the developmental cycle. Alternatively, the 
results could be due to the fact that the participants were all students enrolled in the daily 
rigors of university academics that requires consistent cognitive challenges (i.e. they are 
highly cognitively active). The results could also be due to an interactive effect between 
age and cognitive activity levels among university students. Follow-up studies could help 
to clarify the results picture by testing young, non-university students in the general 
population.  
In conclusion, much work remains to be done in order to disentangle the 
relationship between MPOD in the visual system and in the brain and their on ocular 
health and cognitive functioning in the in humans as we age. 
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Tables 
Table 1 
Demographic Data 
 Low MPOD High MPOD 
 N M SD N M SD 
Age 25 21.60 5.11 25 21.96 4.85 
Sex 25 1.76 .436      25    1.64 0.49 
Education 25 14.32 1.55 25 14.40 1.61 
Sex: 1= Male, 2 = Female 
Education: Number of years in school 
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Table 2 
Cognitive Assessments 
Test Assessment  Task 
Verbal Memory Verbal Learning          
Memory for Words 
Word Recognition        
Immediate and Delayed Recall 
Fifteen Words are presented one 
by one. 
For immediate recognition 
subjects have to recognize those 
words nested among 15 new 
words. Than after 8 more tests 
there is a delayed recognition trial.         
Visual Memory                    Visual Learning                               
Memory for Geometric Shapes   
Geometric Shape Recognition     
Immediate and Delayed Recall   
Fifteen shapes are presented one 
by one. 
For immediate recognition 
subjects have to recognize those 
words nested among 15 new 
words. Then after 7 more tests 
there is a delayed recognition trial. 
Finger Tapping              Motor Control         
Fine Motor Control                         
Participants are required to press 
the space bar with their right index 
finger as many times as they can 
in 10 seconds. This process is 
repeated with their left index 
finger. 
Symbol Digit Coding          Information Processing Speed 
Complex Attention 
Visual Perceptual Speed                   
                  
This test consists of serial 
presentations on the screen, each 
consisting of 8 symbols above and 
empty boxes below. Participants 
are presented with a key indicating 
what symbols correspond with 
each number.  
The participant enters the number 
that corresponds with the 
highlighted symbol. 
Stroop Test                         Simple Reaction Time 
Complex Reaction Time 
Stroop Reaction Time 
Inhibition/Disinhibition  
Frontal or Executive Skills 
Processing Speed 
Words are presented in black and 
the participant presses space bar as 
soon as they see the word.  In the 
second part participants press 
space bar when the color and the 
word match.  In the third part 
participants press space bar when 
the color does not match the words 
meaning. 
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Shifting Attention Test      Executive Function 
Shifting Sets and Rules 
Rapid Decision Making 
Reaction Time             
This test measures the ability to 
shift from one set of instructions 
to another quickly. Three figures 
appear on the screen, one on top 
and two on the bottom.  
Participants are asked to match 
one of bottom shapes to the top 
either by shape or color as the 
rules change rapidly.    
Continuous Performance Sustained Attention 
Reaction Time 
 Impulsivity                                                                                 
A series of letters is flashed on the 
screen.  Participants are asked to 
press the space bar when the letter 
B is flashed. 
Non-Verbal Reasoning       Reasoning 
Reasoning Recognition Speed      
This test is comprised of 15 visual 
analogies that get progressively 
harder.  Participants must decide 
what shape goes in the empty box. 
Four Part Performance       Sustained Attention                      
Working Memory                          
This is a four part test.  Part one is 
simple reaction time.  Part two 
measures choice reaction time. 
Part three is a one back test.  
Participants are only supposed to 
respond if the figure on the screen 
is the same as the previous figure.  
Part four is a two back continuous 
performance task.   
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Table 3 
 
 
Low vs. High MPOD on Cognitive Ability  
Measures  Low MPOD High MPOD   
M SD M SD F p 
Memory 71.44 24.54 61.12 28.67 1.19 .18 
Psychomotor Speed 48.48 26.17 52.88 31.50 0.29 .59 
Reaction Time 65.08 22.81 54.24 34.00 1.75 .19 
Complex Attention 46.76 30.13 44.32 31.69 .08 .78 
Cognitive Flexibility 53.60 32.88 48.04 33.45 .35 .56 
Processing Speed 46.40 32.79 53.08 33.31 .51 .48 
Executive Function 56.60 29.89 50.48 32.92 .47 .50 
Verbal Memory 71.52 28.88 60.40 31.32 1.70 .20 
Visual Memory 64.04 24.05 61.00 31.99 .14 .71 
Reasoning 46.80 31.19 53.32 28.12 .60 .44 
Working Memory 55.52 30.54 49.96 28.65 .44 .51 
Sustained Attention 52.20 23.99 52.64 26.74 0.00 .95 
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Table 4.   
 
Correlation Matrix of Dependent Variables 
Measures 1  2 3 4 5 6 7 8 9 10 11 12  
1. Memory -            
2. Psychomotor Speed .30* -           
3. Reaction Time .46** .65** -          
4. Complex Attention .26 .30* .22 -         
5. Cognitive Flexibility .32* .46** .51** .86** -        
6. Processing Speed .19 .70** .47** .70** .61** -       
7. Executive Function .32* .44** .52** .81** .98** .60** -      
8.Verbal Memory .76** .29* .31* .31* .25 .07 .23 -      
9.Visual Memory .78** .14 .35* .08 .20 .18 .21 .23 -    
10. Reasoning .10 .27 .06 .29* .28* .28* .22 .24 .00 -   
11.Working Memory .44** .56** .38** .52** .62** .62** .60** .39** .27 .25 -  
12.Sustained Attention .35* .52** .40** .43** .54** .63** .53** .38** .14 .24 .81** - 
 
